Navigation Links
CPF, Pulmonary Fibrosis Experts Guests on Sirius and XM Satellite Radio Show June 16th
Date:6/15/2009

"Doctor Radio" Host Interviews CPF Co-Founder, PF Advocate, and Top PF Researcher and Clinician

NEW YORK, June 15 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) today announced its co-founder and other Pulmonary Fibrosis (PF) experts will be guests on the Sirius and XM Satellite Radio Show "Doctor Radio" on Tuesday, June 16th from 6-7 a.m. EDT. For non-Sirius and XM radio subscribers, the show can be heard via a free pass available on the Internet.

Sirius and XM Satellite Radio Interview with CPF, PF Experts

Show: Doctor Radio

Host: Frank Adams, MD

Subject: Pulmonary Fibrosis

Guests: Coalition for Pulmonary Fibrosis Chief Operating Officer and Co-Founder Mark Shreve; Family member of PF patient, legislative advocate and CPF fundraiser Terence Hales; and pulmonologist and world renowned PF researcher and clinician, Maria Padilla, MD, of Mount Sinai Medical Center in New York City.

Date: Tuesday, June 16th, 2009

Time: 6-7 a.m., EDT

Listen online: To listen to the interview online, sign up with an email address for a free pass at http://www.sirius.com/freetrial/register.

Listeners can hear the show live on Tuesday, June 16th or can listen to the repeat which airs from 4-6 p.m. EDT on Tuesday, June 16th. Sirius and XM Satellite Radio subscribers can also listen in on satellite radio.

About Pulmonary Fibrosis (PF)

Pulmonary Fibrosis (PF) is a lung disorder characterized by a progressive scarring - known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from PF, and there is currently no known cause or cure. An estimated 48,000 new cases are diagnosed each year. PF is difficult to diagnose and an estimated two-thirds of patients die within five years of diagnosis. Sometimes PF can be linked to a particular cause, such as certain environmental exposures, chemotherapy or radiation therapy, residual infection, or autoimmune diseases such as scleroderma or rheumatoid arthritis. However, in many instances, no known cause can be established. When this is the case, it is called idiopathic pulmonary fibrosis (IPF).

About the CPF

The CPF is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for pulmonary fibrosis (PF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure PF; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of PF issues; and works to improve awareness of PF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 19,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with PF. For more information please visit www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
2. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
3. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
4. Resolution Recognizing Pulmonary Fibrosis Challenges Overwhelmingly Passes House
5. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
6. Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF
7. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
8. A new method allows for the early diagnosis of pulmonary hypertension
9. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
10. Free Program Dec. 1 to Help Patients With Debilitating Pulmonary Disorder Alpha-1
11. Evel Knievel Lost to Pulmonary Fibrosis; Disease Claims as Many Lives as Breast Cancer Each Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical ... neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse ... is a newly patented safety device secured by nasal surgeons onto the floor of ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
Breaking Medicine Technology: